Does Mounjaro Lower Blood Pressure? What Clinical Trials Found

What the SURMOUNT trial data actually recorded

The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed 2,539 adults with obesity over 72 weeks. Alongside the headline weight-loss results, researchers recorded cardiovascular secondary endpoints. Systolic blood pressure fell by roughly 6–7 mmHg at the 15mg dose; diastolic pressure also dropped, though by a smaller margin. These reductions appeared dose-dependent, people on higher doses of tirzepatide tended to see greater falls than those on lower ones. Across the broader SURMOUNT programme, involving thousands of adults, the blood pressure signal was consistent.

Can tirzepatide lower blood pressure? The trial data says yes, at a group level, in people with obesity. That said, individual responses vary. Some participants saw larger reductions; a minority saw little change. The magnitude also tracked how much weight a person lost, which points to weight reduction as a primary driver rather than a direct pharmaceutical action on blood vessels.

It is worth being clear about what the trial measured: these are observed secondary outcomes, not pre-specified primary endpoints for hypertension. The evidence is real, but Mounjaro is not a blood pressure medicine.

Why the blood pressure drop probably happens

Excess body weight raises blood pressure through several routes: increased blood volume, higher cardiac output, and inflammatory effects on vessel walls. As tirzepatide reduces body weight (typically by 15–20% at the highest dose over 72 weeks in trial conditions) those mechanical and metabolic burdens ease. Blood pressure tends to follow.

There is also emerging research into whether GLP-1 receptor activation has more direct vascular effects, including modest natriuresis (increased sodium excretion by the kidneys) and direct effects on vessel tone. The NHS tirzepatide medicines page describes the dual GIP and GLP-1 mechanism in plain terms. The short answer is that the blood pressure effect almost certainly has more than one cause, and the relative contribution of each is still being studied.

For people who already take antihypertensive medication, this matters practically. If you lose significant weight on tirzepatide and your blood pressure falls, your existing medication may need adjusting, not because tirzepatide interferes with it, but because your blood pressure may genuinely be lower. That kind of review sits with the prescriber managing your hypertension.

Hypertension as an eligibility factor, and what this doesn't mean

Under the UK licence, Mounjaro can be prescribed for adults with a BMI of 27 or above if they have at least one weight-related health condition. High blood pressure (hypertension) is one such condition. So if you have a BMI of 28 and a diagnosis of hypertension, you may be within the licensed criteria for treatment. Whether you're a suitable candidate involves more than that single data point, which is why every prescription requires a clinical assessment rather than a BMI calculator alone.

You can start a free consultation with our prescribers to have your situation reviewed properly. Separately, if you want to understand more about tirzepatide's other cardiovascular effects, our page on how Mounjaro affects blood pressure covers the full picture, including situations where blood pressure can fall too far.

What does Mounjaro lower blood pressure mean in practice? Not that you should stop antihypertensive medication, adjust doses yourself, or assume tirzepatide will manage your hypertension. It means that under clinical supervision, some people with obesity and high blood pressure see improvements in both simultaneously, and if you want to explore whether Mounjaro could help in your specific situation, our guide to whether Mounjaro can help lower blood pressure walks through what the evidence does and does not support. That is genuinely good news, but it needs to be managed, not assumed.

Monitoring and the practical side

If you start tirzepatide and have hypertension or take blood pressure-lowering medicines, keeping a simple log of home readings is reasonable. Most pharmacy-grade arm cuffs take a reading in under a minute, and tracking trends over a few weeks gives your prescriber meaningful data if your dose changes or your other medicines need review. It's a habit that costs almost nothing and can catch a clinically useful pattern early.

A few practical points drawn from the evidence. GI side effects (nausea, vomiting, loose stools) are common in the early weeks, and severe vomiting can cause dehydration. Dehydration reduces blood volume and can temporarily lower blood pressure more than expected, occasionally causing dizziness when standing. This is a short-term effect of GI illness rather than the medicine's direct action, but it is one reason to stay well hydrated, particularly after a dose increase. For a broader look at what to expect, our guide to Mounjaro's side effects covers the full GI profile and what typically settles with time.

People taking tirzepatide who have concerns about low readings, dizziness, or how their other medicines are interacting should speak to their prescriber. Our page on low blood pressure and Mounjaro addresses that situation specifically. And if you're trying to piece together whether tirzepatide raises or lowers readings in different circumstances, the page on whether Mounjaro raises blood pressure completes the picture.